Drug Week articles from February 2002

Drug Week archives from February 2002

Erythropoietin With Aminoguanidine Improves Red Blood Cell Deformability.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in New York say that the hormone growth factor erythropoietin (EPO), in combination with the antiaging drug aminoguanidine (AG), can reduce red...

Many Azole Antifungal Drugs Affect P Glycoprotein Transport.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Many commonly used azole antifungal medicines have a pronounced effect on P glycoprotein activity, according to researchers in the United States. "Both...

Cyclin-Dependent Kinase Inhibitors May Be Effective Against HIV Nephropathy.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States say that cyclin-dependent kinase inhibitors may be an effective treatment for patients with HIV related kidney dysfunction ...

Adding Vitamin C To Certain Drugs May Help Treat Senility.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Drugs used to treat Alzheimer and other brain disorders appear to enter the brain more easily when a vitamin C molecule is attached, according to researchers in Italy. The discovery could lead to safer...

Florida Suicide Pilot Took Controversial Drug Accutane.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- A 15-year-old student pilot who killed himself by crashing an airplane into a skyscraper was prescribed an acne medication whose links to suicide and depression have been the subject of federal...

Broad-Spectrum Cephalosporins Ineffective Against Most Ceftazidime-Resistant Enterobacteria.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Broad-spectrum cephalosporins have only limited usefulness in the treatment of ceftazidime-resistant enterobacterial infections, researchers in the United...

Multidrug Resistance Gene May Not Affect Mefloquine Susceptibility.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Contrary to conventional wisdom, researchers in Europe and Africa report that mutations in a malaria gene linked to multidrug resistance may not affect the...

Sirolimus Effective But Dangerous As Salvage Graft-Versus-Host Therapy.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States say that sirolimus is an effective - but risky - second-line therapy for severe graft-versus-host disease (GvHD). Dr. Ana...

AxCell Biosciences Expands Management, Forms Scientific Advisory Board.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- AxCell Biosciences, a subsidiary of Cytogen Corp. (CYTO) and a provider of intracellular signaling pathway information for the pharmaceutical and biotechnology research industries, will add a chief...

SkyePharma Names Global Head of Business Development.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- SkyePharma PLC (SKYE, SKP) has appointed Dr. Paul Wotton as global head of business Development. Wotton was most recently vice president of corporate development at Eurand International BV, Italy,...

William Kerns Joins Scientific Advisory Board of Ricerca.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Ricerca, LLC, a drug development company, has announced the appointment of William D. Kerns, DVM, MS, to its scientific advisory board. "Dr. Kerns' senior-level experience in worldwide R&D in the...

Study Data On Imatinib Mesylate Prompts Major Protocol Changes.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- In an interim analysis of the ongoing Phase III study comparing Gleevec (imatinib mesylate) to standard therapy (interferon injections plus Ara-C [cytarabine] chemotherapy) for initial treatment in...

NewBiotics Begins NB1011 Phase I/II Clinical Trial.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- NewBiotics, Inc., has commenced a Phase I/II clinical trial of NB1011 for patients with colon cancer. Developed under a joint venture with Elan Corp., NB1011 is the first product derived from...

Study To Evaluate Outpatient Use Of Nesiritide.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Scios, Inc., announced January 3, 2002, that it has begun enrolling patients in a pilot study designed to evaluate the safety and tolerability of Natrecor (nesiritide) when administered in an outpatient...

Human Proof-Of-Principle Study Using Oral Ceftriaxone Successful.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., announced successful results from a human clinical research study examining the bioavailability of ceftriaxone in a variety of oral formulations. In these studies,...

P113D Has Antibacterial Activity Against Cystic Fibrosis Infections.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Demegen, Inc., announced that study results indicate that P113D holds promise as an inhalant therapy for cystic fibrosis (CF) patients. The results published in this study suggest that P113D not...

Ranbaxy Receives Tentative Approval For Loratadine 10-mg Tablets.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Ranbaxy Pharmaceuticals, Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL) of New Delhi, India, announced this month (January 2002) U.S. Food and Drug Administration (FDA)...

Concurrent Use Of Prescription Drugs, Herbs Raises Concerns.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- In any given week, most U.S. adults take at least one medication, and one in six patients taking prescription drugs also use herbal products or other natural supplements, posing potential risks of...

Esomeprazole Well-Tolerated And Efficacious As Maintenance Therapy.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Some 90% of clinical trial participants remained disease free from erosive esophagitis for up to 12 months after a maintenance regimen with Nexium (esomeprazole). Erosive esophagitis is a more...

Prescription Drug Use Varies Widely Among States.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Until now, your age and gender were among the best indicators of how you might use prescription drugs. Now, a comprehensive state-by-state study of prescription drug use reveals where you live also can...

Investigational New Drug Application For Gallium Nitrate Submitted.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Genta, Inc., announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for the study of gallium nitrate in patients with non-Hodgkin...

Most B-Vitamin Supplements Contain Stated Minimums But Often Exceed Safe Levels.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- ConsumerLab.com announced January 8, 2002, that all but one of the 21 products analyzed in its B Vitamin Product Review contained the claimed amounts of B vitamins. However, nine of the products...

ISTA Pharmaceuticals Submits Initial Section of Vitrase NDA.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- ISTA Pharmaceuticals, Inc., (ISTA) has submitted the initial section of the New Drug Application (NDA) for Vitrase, a drug being developed by the company for the treatment of patients with severe...

Vernalis Announces New Development Program.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Vernalis (VER) has selected a lead development compound in its adenosine A(2A) receptor antagonist research program targeting Parkinson disease. The company will now complete the preclinical program on...

Regulated Systems Hosting For Pharmaceutical And Healthcare Applications Released.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- TRW, Inc., has introduced outsourced hosting services to help pharmaceutical and healthcare companies comply with international and U.S. Food & Drug Administration (FDA) information-technology...

Exelixis and Schering-Plough Collaborate on Customized Compound Library.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Exelixis, Inc., (EXEL) has entered into a strategic collaboration with Schering-Plough Research Institute to create a customized high-throughput screening compound collection to be utilized by both...

Risperdal Can Decrease Risk Of Relapse In Long-Term Treatment Protocol.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- A study found that patients with stable schizophrenia or schizoaffective disorder have less risk of the symptoms' returning when they receive atypical antipsychotic medication, Risperdal (risperidone),...

Program Initiated To Prevent Accutane-Exposed Pregnancies.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Hoffmann-La Roche, Inc., working closely with the U.S. Food and Drug Administration (FDA), is distributing an enhanced version of their Pregnancy Prevention Program for Women on Accutane (PPP) to more...

Israeli Start-Up Gets Healthy Start from Global Healthcare Giant.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Novartis Pharma AG has contracted Optimata, Ltd., an Israeli biosimulation start-up to utilize its proprietary mathematical algorithms and software tools in conjunction with clinical and preclinical...

Tripos Partners With Pfizer in Software Agreements.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Tripos, Inc., (TRPS) has signed a multimillion dollar, multiyear agreement with Pfizer Global Research and Development (PFE) to license its suite of discovery software technologies, including the SYBYL...

Improved Daily Glucose Profiles With Pramlintide Acetate Therapy Reported.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., announced results from a six-week pilot study examining the effects of Symlin (pramlintide acetate) on the daily glucose profile in people with type 1 diabetes who are...

Positive Results From Continuous Infusion Study Of AC2993 Announced.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- Amylin Pharmaceuticals, Inc., announced results from a study examining the effects of sustained circulating concentrations of AC2993 (synthetic exendin-4) on glucose concentrations over a 24 hour period...

NicOx Granted IND Status for Clinical Testing of HCT 1026 in the U.S.
February 1, 2002... 2002 FEB 1 - (NewsRx.com & NewsRx.net) -- NicOx's Investigational New Drug application (IND) has been accepted by the U.S. Food and Drug Administration (FDA) for the clinical testing of HCT 1026, the company's nitric oxide-releasing derivative...

Chloride Ion Channel Strikingly Different From Potassium Kin.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- "Why did nature come up with such a structural plan?" ask Rockefeller University professor Roderick MacKinnon and colleagues describing the three-dimensional structure of a type of chloride channel...

Arsenic Trioxide Works Through Caspase Pathway.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The antineoplastic agent arsenic trioxide uses the caspase pathway to induce apoptosis in leukemic cells, researchers in the United States and France report....

Extended-Release Fluvastatin Sodium Long-Term Data Is Encouraging.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- A retrospective analysis study shows Lescol XL, the only approved extended-release statin formulation, has a low incidence of creatine phosphokinase (CPK) elevation. The pooled analysis includes...

Low Cefotaxime Doses Produce Hypermutable Streptococcus Strains.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Minute doses of the antibiotic cefotaxime can produce Streptococcus pneumoniae strains with augmented mutation capacities, researchers in Spain report. ...

Ifosfamide-Vinorelbine Regimens Effectively Mobilize Stem Cells For Transplant.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Chemotherapy regimens based on ifosfamide and vinorelbine can effectively mobilize hematopoietic stem cells for harvesting and autologous transplantation,...

FDA Approves First Room-Temperature MS Treatment Option.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Berlex Laboratories, Inc., the U.S. affiliate of Schering AG, Germany, and Chiron Corporation announced the approval of a new room-temperature formulation of Betaseron (interferon (beta)-1b) for...

Anticoagulant Drugs Can Lower Endothelial Protein C Receptor Levels.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Some anticoagulant drugs reduce levels of a protein C receptor in humans, researchers in the United States and Europe say. "The endothelial protein C...

Tests Reveal No Systemic Adverse Effects From MDI-P.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Medical Discoveries, Inc., (MDI) announced that test results from WIL Research Laboratories have indicated that MDI-P, MDI's proprietary AIDS drug, produced no systemic toxicity in laboratory animal...

Squalamine Trial For The Treatment Of Fibrodysplasia Ossificans Progressiva Initiated.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Genaera Corporation announced the initiation of a clinical trial for squalamine, its antiangiogenic agent, in fibrodysplasia ossificans progressiva (FOP). The study will be conducted in...

TKT Announces New Additions to Management Team.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Transkaryotic Therapies, Inc., (TKTX) has announced two new management appointments and a promotion. TKT has appointed David D. Pendergast, PhD, formerly vice president of development and quality...

Kendle International Enters into Strategic Alliance with Pharmacia Corp.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Kendle International, Inc., (KNDL) has entered into a 3-year strategic alliance as a primary provider of global clinical services to Pharmacia Corp. The alliance expands on Kendle's longstanding...

Results From Phase III Daptomycin Trial Show Geographic Differences.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Cubist Pharmaceuticals, Inc., announced preliminary results from the first of two pivotal, Phase III trials investigating the safety and efficacy of its investigational antibiotic Cidecin (daptomycin...

New Pharma Chemistry in Drug Discovery Meeting Slated for April 4-5.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Leading pharmaceutical and biotech companies from the pharmaceutical and medicinal chemistry communities will convene at the "New Pharmaceutical Chemistry Accelerating Drug Discovery" Conference &...

Atrix Submits Second Abbreviated New Drug Application to FDA.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Atrix Laboratories, Inc., (ATRX) has submitted a second Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval of a generic equivalent to an undisclosed...

CyDex Licenses Captisol to Pfizer in First Application for Animal Health Products.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- CyDex, Inc., an innovator in drug delivery technologies, has announced its first agreement for use of the advanced formulation system, Captisol, in animal health products. CyDex has licensed Captisol...

Landec Announces $2.5 Million License and R&D Agreement With UCB, S.A.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Landec Corp. (LNDC) has entered into an exclusive licensing and research and development (R&D) collaboration with Belgium-based UCB, a large multinational specialty chemical and pharmaceutical company....

Technology Allows Conversion Of Peptide Drugs Into Small Molecules For Oral Administration.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Keryx Biopharmaceuticals, Inc., announced that it has obtained an exclusive worldwide license to a novel technology known as small integrated building-blocks (SIB), for the conversion of peptides and...

Inbuilt Antibiotics Inspire Drug Design.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Humans, plants, and animals live, by and large, harmoniously with microbes. A recently published review article by Michael Zasloff of the University of Pennsylvania School of Medicine, Philadelphia,...

ComGenex and Solvo Biotech Reach Key Milestone in Joint Drug Discovery Program.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- ComGenex, Inc., of Budapest, and Solvo Biotechnology, Inc., Szeged, Hungary, have filed an application for patent protection of drug candidates resulting from a collaborative discovery and development...

Tripos Targets Continued Strong Growth in 2002 Following Record Fiscal 2001.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Tripos, Inc., (TRPS) expects continued revenue and earnings growth in 2002, following record results for the full year of 2001. The fourth quarter of 2001 will be the company's fifth consecutive...

Drugs To Target Patients Based On Their Genetic Make Up.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Genaissance Pharmaceuticals, Inc., announced that enrollment has been completed for its second prospective clinical trial, STRENGTH II. The STRENGTH (Statin Response Examined by Genetic HAP Markers)...

Microarrays Measuring 2000 Cell Phenotypes Completed.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Biolog, Inc., announced the achievement of a major milestone January 14, 2002, at the Cambridge Health Institute's (CHI's) Fourth Annual Conference, "Lab-on-a-Chip and Microarrays for Post-Genome...

Oral Suspension Formulation Of Proton Pump Inhibitor Now Available.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Prevacid for Delayed-Release Oral Suspension now is available by prescription nationwide, providing greater versatility for patients who have difficulty swallowing capsules. Developed by TAP...

Drug Safety Alert Issued To Help Protect Against Lindane Toxicity.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Pharmaceutical Care Network (PCN) is alerting physicians of patients in California with an immediate history of Lindane use about the product's toxicity. A new California law implemented January 1,...

Positive Phase Ia Clinical Trial Results For XTL-002 Announced.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- XTL Biopharmaceuticals, Ltd., announced positive clinical data on the antiviral activity and safety of XTL-002, being developed for the treatment of hepatitis C virus (HCV) infections. Results of...

Phase III Interferon (gamma)-1b Study To Continue As Planned.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- InterMune, Inc., announced in January, 2002, that the Data Safety Monitoring Board (DSMB) for its Phase III clinical trial of Actimmune (interferon (gamma)-1b) injection for the treatment of idiopathic...

Pharmaceutical Resources to Acquire ISP FineTech Fine Chemical Business.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Pharmaceutical Resources, Inc., (PRI) intends to acquire the International Specialty Products (ISP) FineTech fine chemical business. ISP FineTech, based in Haifa, Israel, and Columbus, Ohio,...

Phylos Announces Formation of Phylos GmbH.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Phylos, Inc., has entered into an agreement with Aventis Research & Technologies and one of its subsidiaries (AR&T) in Frankfurt, Germany, under which Phylos has acquired a division of AR&T and created...

Investigators Train For Upcoming Clinical Trial.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Cortex Pharmaceuticals, Inc., and Les Laboratoires Servier, of Paris, France, began a two-day training meeting January 18, 2002, for clinical investigators involved in an upcoming international clinical...

Akorn Receives FDA Approval to Launch Paremyd.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Akorn, Inc., has received FDA approval to market Paremyd (hydroxyamphetamine hydrobromide 1% and tropicide 0.25%), a topical mydriatic/cycloplegic combination product that Akorn acquired from Allergan,...

Phase III Clinical Trial Data Of INS365 For Dry Eyes Presented.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Inspire Pharmaceuticals, Inc., announced top line preliminary efficacy results from the first of two Phase III clinical trials for INS365 Ophthalmic eye drops for the treatment of dry eye. These...

Phase III Studies For ProSorb-D Pain Product Initiated.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- aaiPharma, Inc., has enrolled and administered doses to the first group of patients in its pivotal Phase III clinical trials for its ProSorb-D (diclofenac) pain product. There were promising...

Proof Of Concept Phase I Study For Buccal Morphine Completed.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation announced that it successfully completed a proof of concept, Phase I clinical study of morphine delivery using its proprietary RapidMist technology. The study...

Daytime Sleepiness Not Associated With Parkinson Drugs.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Excessive daytime sleepiness is common among patients with Parkinson disease - even those who are independent and do not have dementia. But daytime sleepiness and falling asleep while driving are not...

Melatonin Receptor Agonist Ly 156735 Shows Positive Results.
February 8, 2002... 2002 FEB 8 - (NewsRx.com & NewsRx.net) -- Phase 2 Discovery, Inc., announced that it has entered into an exclusive agreement with Eli Lilly and Company to develop and market the melatonin receptor agonist LY 156735 worldwide. Preliminary...

High-Dose Cytosine Arabinoside-Based Regimens Effective As Salvage Therapy.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in California say that high-dose cytosine arabinoside (Ara-C)-based chemotherapy regimens can provide some hope for HIV patients with refractory or...

Quinolone Treatment Increases Risk Of False-Positive Drug Tests.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Quinolone antimicrobial medicines can increase the risk of testing positive for illicit opiates, researchers in the United States say. "Millions of assays...

Rifampicin Reduces Nevirapine Levels In Coinfected Patients.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The antituberculosis drug rifampicin lowers in vivo levels of the antiretroviral agent nevirapine, researchers in Spain report. Dr. Esteban Ribera and...

Signal Transduction Inhibitor 571 Has Little Effect On Most Malignant Cells.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in Texas say that, contrary to previous reports, signal transduction inhibitor 571 (STI571) does not effectively prevent acute myelogenous leukemia...

Molecular Clamp Shuts Down Cancer-Causing Protein.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Many of today's medicines were discovered by trial and error: a substance is found that helps alleviate the symptoms of a disease, and it may take years before scientists really understand how it...

Clinical Trial Tests Gel For Treatment Of Precursor To Skin Cancer.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Researchers at Fox Chase Cancer Center, Philadelphia, Pennsylvania, are conducting an innovative clinical trial using bexarotene (Targretin), a form of vitamin A in a topical gel, to treat...

Protein May Be Target For New Cancer Drugs.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- During development of multicellular organisms, cells are bombarded by signals from their environment. The repertoire of receptors that cells display on their surfaces often determines whether or not...

Atorvastatin Improves Blood Rheology.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - The lipid-reduction drug atorvastatin (Lipitor) improves blood flow in patients undergoing treatment for familial hypercholesterolemia (FH), according to...

Carolyn Rynard Named VP Of Product Development.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Medinox, Inc., announced that Carolyn Rynard, PhD has been appointed to the position of Vice President of Product Development. In this position, Rynard will be directly responsible for Medinox's...

Charles Deignan Promoted To Senior Director.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- AtheroGenics, Inc., (AGIX) a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced the promotion of Charles A. Deignan to senior director of Finance and...

John Hotchkiss Joins AnVil Informatics.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- AnVil Informatics, Inc., a provider of in silico drug discovery services, has appointed John Hotchkiss to chief technology officer. Hotchkiss brings an extensive background in managing technology for...

New Chief Executive Officer Named.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Restoragen, Inc., a developer of regulatory peptide therapies for age-related diseases, announces the appointment of Ashleigh W. Palmer as chief executive officer. Palmer brings to Restoragen over...

Tracy Tsuetaki Joins Quintiles Transnational.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Quintiles Transnational Corp. (QTRN) announced the following executive appointment of Tracy K. Tsuetaki, OD, as senior vice president, Global Business Development. In this newly created position,...

William Claypool Joins 3-Dimensional Pharmaceuticals Board.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- 3-Dimensional Pharmaceuticals, Inc., (DDDP) announced the appointment of William Claypool, MD, to its Board of Directors. Claypool has enjoyed a prominent career spanning teaching, research,...

Shire Pharmaceuticals Will Combat Generic Competition With Adderall XR.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Attention-deficit/hyperactivity disorder is a new Decision Resources study that explains why this highly prevalent disorder remains significantly underdiagnosed and undertreated in most of the major...

Endo Pharmaceuticals Extends Warrant Tender Offer.
February 15, 2002... 2002 FEB 15 - (NewsRx.com & NewsRx.net) -- Endo Pharmaceuticals Holdings, Inc., (ENDP) is experiencing slower than anticipated patient enrollment in clinical studies for its development-stage drug MorphiDex. The Company has instituted steps...